Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 838-chemotherapy-with-acute-leukemia-as-secondary-diagnosis-with-cc-or-high-dose-chemotherapy-agent
    Ask Trek AI about this page

    Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent: Inpatient Reimbursement Overview

    DRG 838 applies to inpatient chemotherapy admissions when acute leukemia is a secondary diagnosis with a Complication or Comorbidity or when a high dose chemotherapy agent is used. This Diagnosis-Related Group reflects the higher resource intensity and drug-related costs that influence Medicare inpatient reimbursement.

    Customize your policy alerts

    Sign up for drg 838 policy alerts

    Get alerted when payer policies referencing 838 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 838 Overview

    DRG 838 covers inpatient admissions for chemotherapy where acute leukemia is listed as a secondary diagnosis with a Complication or Comorbidity or when a high dose chemotherapy agent is administered. This grouping captures resource use related to inpatient chemotherapy delivery, management of chemotherapy-related toxicity, and monitoring for complications in patients with acute leukemia. It matters for Medicare payment because it aligns reimbursement with expected intensity of care, drug costs, and ancillary services required during the admission. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and the associated payment tier.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating optimal acute inpatient chemotherapy regimens and dosing strategies for patients admitted primarily for chemotherapy who have acute leukemia as a secondary diagnosis or who require high‑dose chemotherapeutic agents. These studies enroll hospitalized adults and children receiving intensive induction or consolidation therapy, often with close monitoring for neutropenia and organ toxicity, and compare different dosing schedules, supportive care bundles, or inpatient administration protocols. Results inform providers on balancing efficacy and toxicity during the high‑risk inpatient phase and help payers anticipate resource use tied to length of stay, transfusion needs, and complications.
    • Comparative effectiveness research comparing inpatient versus outpatient administration pathways and supportive-care strategies for high‑dose chemotherapy recipients with acute leukemia as a comorbidity. These pragmatic studies assess readmission rates, infection complications, emergency visits, and total cost of care in populations stratified by performance status, social support, and comorbidity burden to determine which patients can be safely managed in lower‑acuity settings. Findings are directly relevant to discharge planning, utilization management, and reimbursement policies by identifying candidates for care-site shifts that maintain safety while reducing inpatient resource utilization.
    • Post‑discharge outcomes and survivorship studies focused on short‑term morbidity, unplanned readmissions, and functional recovery after hospitalization for chemotherapy in patients with concurrent acute leukemia. Cohorts track 30‑ and 90‑day outcomes, including infection, bleeding events, transfusion dependence, and need for home health or rehabilitation services, often linking clinical data with claims to quantify downstream costs. This research helps providers and payers identify high‑risk subgroups needing intensified transitional care or case management and supports value‑based payment models by highlighting drivers of post‑hospitalization utilization.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.